Kordata Dynamics emerged from stealth to deploy neural recording and monitoring tools inside health systems for clinical trials. BIOS Health supplied the core IP, retains majority ownership, and Emil Hewage will lead Kordata as CEO with Dawn McCollough as president.
The company says it is pursuing a $26 billion opportunity to reduce the CNS clinical-trial backlog by turning large hospitals and academic medical centers into trial sites with built-in neural data capability. Kordata will partner with those systems to install recording, transmission and trial workflows and charge volume-based licensing fees plus sponsorship fees when sites run new trials.
Hewage described the target customers as life‑science firms “specifically those that have very precise products, with tight dosing ranges or unique inclusion criteria, who are designing novel trials.” He said initial focus areas include Alzheimer’s, Parkinson’s and epilepsy, with longer-term interest in drug‑resistant conditions across cardiology and immunology.
The company’s technical foundation is BIOS’s NeuroTune platform, which it says provides real‑time dosing guidance by measuring individual neural responses. Kordata positions NeuroTune as a plug‑and‑play layer that can ingest signals from implanted systems and wearable sensors and route those data into clinical research workflows while meeting IRB and CRO requirements, the company said. “The nervous system is the fastest thing to react in your body to pretty much most medical interventions,” Hewage told the author. “You’re really at the millisecond level, looking at organ responses and brain responses.”
Kordata held a private launch event a few weeks ago that attendees described as including leaders from the Royal College of Surgeons, NVIDIA, municipal officials, startups and investors including Kern Venture Group, MAVRK Celestia Fund, and Digital Neural Infrastructure Holdings. The company is based in Bakersfield, California; executives said the local mix of public payers and clinical volume makes recruitment attractive to life‑science partners.
Background: Kordata frames its timing alongside broader moves to faster, data‑rich trials, including recent regulator and industry interest in real‑time trial data. The company’s claims about performance and clinical impact are presented as company statements and not yet independently published.
Photo credit: imageio.forbes.com
Tags: neurotechnology, clinical trials, neural recording, wearables
Topics: Neurotech industry & startups, Wearable neurotech, Neuroprosthetics & neural implants